Cássia R Silva1, Sara M Oliveira1, Carin Hoffmeister2, Vinícius Funck2, Gustavo P Guerra3, Gabriela Trevisan1, Raquel Tonello1, Mateus F Rossato1, João B Pesquero4, Michael Bader5, Mauro S Oliveira2, Jason J McDougall6, Juliano Ferreira7. 1. Graduate Program in Biological Sciences: Toxicological Biochemistry, Federal University of Santa Maria, Santa Maria, RS, Brazil. 2. Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria, RS, Brazil. 3. Center for Food Sciences, Federal Technologic University of Paraná, Medianeira, PR, Brazil. 4. Department of Biophysics, Universidade Federal de São Paulo, São Paulo, SP, Brazil. 5. Max-Delbrück-Center for Molecular Medicine (MDC) and Charité, University Medicine, Berlin, Germany. 6. Departments of Pharmacology and Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 7. Graduate Program in Biological Sciences: Toxicological Biochemistry, Federal University of Santa Maria, Santa Maria, RS, Brazil Graduate Program in Pharmacology, Federal University of Santa Maria, Santa Maria, RS, Brazil Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.
Abstract
OBJECTIVE: Verify the role of the kinin B1 receptors (B1R) and the effect of ACE inhibitors (ACEi) on acute gout induced by monosodium urate (MSU) crystals in rodents. METHODS: Painful (overt pain and allodynia) and inflammatory parameters (joint oedema, leukocyte trafficking, interleukin-1β levels) of acute gout attacks were assessed several hours after an intra-articular injection of MSU (1.25 or 0.5 mg/articulation) into the ankle of rats or mice, respectively. The role of B1R was investigated using pharmacological antagonism or gene deletion. Additionally, B1R immunoreactivity in ankle tissue and sensory neurons, kininase I activity and des-Arg(9)-bradykinin synovial levels were also measured. Similar tools were used to investigate the effects of ACEi on a low dose of MSU (0.0125 mg/articulation)-induced inflammation. RESULTS: Kinin B1R antagonism or gene deletion largely reduced all painful and inflammatory signs of gout. Furthermore, MSU increased B1R expression in articular tissues, the content of the B1 agonist des-Arg(9)-bradykinin and the activity of the B1 agonist-forming enzyme kininase I. A low dose of MSU crystals, which did not induce inflammation in control animals, caused signs of acute gout attacks in ACEi-treated animals that were B1R-dependent. CONCLUSIONS: Kinin B1R contributes to acute gouty attacks, including the ones facilitated by ACEi. Therefore, B1R is a potential therapeutic target for the treatment and prophylaxis of gout, especially in patients taking ACEi. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Verify the role of the kinin B1 receptors (B1R) and the effect of ACE inhibitors (ACEi) on acute gout induced by monosodium urate (MSU) crystals in rodents. METHODS: Painful (overt pain and allodynia) and inflammatory parameters (joint oedema, leukocyte trafficking, interleukin-1β levels) of acute gout attacks were assessed several hours after an intra-articular injection of MSU (1.25 or 0.5 mg/articulation) into the ankle of rats or mice, respectively. The role of B1R was investigated using pharmacological antagonism or gene deletion. Additionally, B1R immunoreactivity in ankle tissue and sensory neurons, kininase I activity and des-Arg(9)-bradykinin synovial levels were also measured. Similar tools were used to investigate the effects of ACEi on a low dose of MSU (0.0125 mg/articulation)-induced inflammation. RESULTS: Kinin B1R antagonism or gene deletion largely reduced all painful and inflammatory signs of gout. Furthermore, MSU increased B1R expression in articular tissues, the content of the B1 agonist des-Arg(9)-bradykinin and the activity of the B1 agonist-forming enzyme kininase I. A low dose of MSU crystals, which did not induce inflammation in control animals, caused signs of acute gout attacks in ACEi-treated animals that were B1R-dependent. CONCLUSIONS: Kinin B1R contributes to acute gouty attacks, including the ones facilitated by ACEi. Therefore, B1R is a potential therapeutic target for the treatment and prophylaxis of gout, especially in patients taking ACEi. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Marwa Qadri; Gregory D Jay; Ling X Zhang; Wendy Wong; Anthony M Reginato; Changqi Sun; Tannin A Schmidt; Khaled A Elsaid Journal: Arthritis Res Ther Date: 2018-08-29 Impact factor: 5.156
Authors: Carlos F Santos; Ana C Morandini; Thiago J Dionísio; Flávio A Faria; Marta C Lima; Caio M Figueiredo; Bella L Colombini-Ishikiriama; Carla R Sipert; Rubens P Maciel; Ana P Akashi; Gabriela P Souza; Gustavo P Garlet; Camila O Rodini; Sandra L Amaral; Christiane Becari; Maria C Salgado; Eduardo B Oliveira; Isaac Matus; Daniela N Didier; Andrew S Greene Journal: PLoS One Date: 2015-08-05 Impact factor: 3.240